PLK1 as a potential drug target in cancer therapy
✍ Scribed by Kee Chuan Goh; Haishan Wang; Niefang Yu; Yifa Zhou; Yin Zheng; ZeYi Lim; Kanda Sangthongpitag; Lijuan Fang; Mark Du; Xukun Wang; A. B. Jefferson; Janet Rose; Blanche Shamoon; Christoph Reinhard; Brad Carte; Michael Entzeroth; BinHui Ni; Marcia L. Taylor; Walter Stünkel
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 377 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0272-4391
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract It is becoming increasingly clear that angiogenesis plays a crucial role in prostate cancer (CaP) survival, progression, and metastasis. Tumor angiogenesis is a hallmark of advanced cancers and an attractive treatment target in multiple solid tumors. By understanding the molecular basis
## Abstract The tubulin/microtubule system is an important target for anticancer therapy. Two of the most clinically valuable groups of these agents are the __vinca__ alkaloids and taxanes. In recent years, new tubulin‐binding agents have been under preclinical or clinical development. One of these
## Abstract An unexpected result emerging from completion of the genome sequencing project is that a large portion of mammalian genomes is constituted by retrotransposons. A large body of published data supports the conclusion that retrotransposons are biologically active elements and indicates tha
## Abstract The amplification of the q21 band of chromosome 8 (8q21) occurs in a large percentage of breast cancers. WWP1, an HECT domain‐containing ubiquitin E3 ligase located in the 8q21 region, negatively regulates the TGF‐β tumor suppressor pathway. To characterize the role of __WWP1__ in breas